Results 271 to 280 of about 80,027 (384)

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı, Ömer Faruk Akçay, Emre Yaşar, Ülver Derici, Galip Güz   +4 more
wiley   +1 more source

Signs of congestion, quality of life and short‐term rehospitalization in patients with heart failure

ESC Heart Failure, EarlyView.
Abstract Aims Signs of congestion are a treatment target in patients with heart failure (HF), as they affect patients' well‐being, and congestion scores are associated with the risk of early readmission. However, which individual sign of congestion has the strongest association with quality of life (QoL) and HF rehospitalization remains uncertain ...
Geert H.D. Voordes, Adriaan A. Voors, Hailun Qin, Jozine M. ter Maaten, Kevin Damman   +4 more
wiley   +1 more source

Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension. [PDF]

Biomedicines
Schinzari F, Montenero R, Cardillo C, Tesauro M.   +3 more
europepmc   +1 more source

Prescription of guideline‐directed medical therapy in heart failure: impact on mortality and readmission

ESC Heart Failure, EarlyView.
Routine data analysis showing a better outcome regarding mortality and readmission in HF patients when being prescribed the current four‐drug treatment (vs. the outdated two‐drug therapy) 91–365 days after index hospital stay. Abstract Aims The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy ...
Martin Möckel, Samipa Pudasaini, Kristina Feldmann, Henning Thomas Baberg, Benny Levenson, Jürgen Malzahn, Thomas Mansky, Guido Michels, Christian Günster, Elke Jeschke   +9 more
wiley   +1 more source

Heart Failure With Preserved Ejection Fraction: A Fascinating Journey. [PDF]

JACC Case Rep
O'Meara E.
europepmc   +1 more source

Pharmacologic Profile of UR-7247, an Orally Active Angiotensin II AT1 Receptor Antagonist, in Healthy Volunteers

, 2000
Marc Maillard, Julien Rossat, J. Nussberger, Joaquim Ramis, Caridad Pontes, Michel Burnier, Hans R. Brunner   +6 more
openalex   +1 more source

Early prescription of quadruple therapy in acute decompensated heart failure with reduced ejection fraction: A propensity score‐matched analysis

ESC Heart Failure, EarlyView.
This propensity score‐matched analysis of 2051 acute decompensated heart failure patients from the ICARUS registry compared 898 patients who received early quadruple guideline‐directed medical therapy (within 48 h of admission) to 1153 matched controls.
Luis E. Echeverría, Lyda Z. Rojas, Angie Yarlady Serrano‐García, Daniel Botero, Karen Andrea García‐Rueda, Ángela Torres‐Bustamante, Diana Ivonne Cañón‐Gómez, Juan Sebastián Salcedo, Alexandra Hurtado‐Ortiz, Jaime A. Rodríguez, Sergio A. Gómez‐Ochoa   +10 more
wiley   +1 more source

Editorial: Pathogenesis and clinical treatment of diabetic nephropathy. [PDF]

Front Med (Lausanne)
Xu Z, Qiang S, Hu Z, Chen H.
europepmc   +1 more source

Will angiotensin II receptor antagonists be renoprotective in humans?

Kidney International, 1996
openaire   +3 more sources

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
wiley   +1 more source